SREs

What you Need to Know About Denosumab (Xgeva)

Xgeva is used in men with advanced and metastatic prostate cancer with bone metastases for the prevention of developing additional skeletal-related events (not to be confused with bone mineral density). In a phase 3 trial, the 147 Study, evaluating denosumab (Xgeva) versus placebo 1,432 men with castrate-resistant prostate cancer demonstrated that Xgeva improved median bone [...]

By Malecare|2014-06-19T09:53:16-04:00June 19th, 2014|Advanced Prostate Cancer, bisphosphonates, Bone Metastases, denosumab - Xgeva, Drugs & Treatments, General Information, Uncategorized, Understanding APC, Xgeva|0 Comments

Denosumab for the Prevention of Skeletal Events in Men with Castration-Resistant Advanced Prostate Cancer

From: the 2014 ASCO GU Meeting Abstract No: 35 Researchers have found in a randomized controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC) the use of the treatment denosumab was superior to the more commonly used zoledronic acid (ZA) for reducing skeletal-related events (SRE). SREs are defined as a pathological fracture, surgery or [...]

By Malecare|2014-02-11T15:14:16-05:00February 11th, 2014|Advanced Prostate Cancer,